Finding the invisible, how to meet Family Offices
Besides calling the Ghostbusters, how does one catch a ghost? That is the question asked by most life science companies trying to raise capital from family offices
Capital Raising, White Papers
White Papers
Capital Raising, White Papers
Navigating the MedTech Fundraising Environment
For many years, the fundraising environment for MedTech companies has been exceedingly difficult. Venture firms that were historically active in MedTech shifted their investment allocations to other areas of life sciences and capital became constrained.
Locust Walk Institute, White Papers
Demystifying the Venture Capital Term Sheet
Raising capital for an emerging biotech company is rarely easy. Tremendous time and effort goes into crafting the perfect story, determining the amount of capital you need to raise and what that money will be used for and reaching out to investors.
Multitrack Process, White Papers
When to use a structured deal process?
Though often overlooked or made by default, decisions about the structure and timing of a competitive deal process can have a significant impact on the ultimate value realized by the sell-side company.
Asian Capabilities, Partnering, White Papers
Key trends impacting Japan partnering
Over the past years, I have had the fortune of participating in negotiations and ultimate deals between Western and Japanese biopharmaceutical companies.
Commercial Assessment, White Papers
Getting Taken to School: Key Considerations and Differentiators of why “Academic” Transactions Have Typically Lower Deal Values than Industry Transactions
With the new school year just around the corner here in Boston (and already underway in other parts of the country), transactions involving academic
Market Trends, White Papers
Maximizing the Likelihood of Closing a Deal This Year
A few months ago, I posted a related article about deal timing titled ‘Maintaining Deal Momentum in the Summer Months’. Now it is early August, and we are deep in the summer slowdown.
Capital Raising, White Papers
Why is Family Office money so hard to find for life science companies?
As an early advocate for the importance of the family office in the biotech financing landscape, I have learned from recent experience what many entrepreneurs already know. Raising money from family offices is hard.
Partnering, White Papers
Ask the Experts: The Importance of Including Subject Matter Experts in Deal Discussions
One of the most important elements of successful deal discussions is establishing your credibility to a potential partner. This can be done in a multitude of ways
Asian Capabilities, White Papers
Helping to Ensure Success After the Deal
One of my favorite places to hang out in Tokyo is the Apple Store in the Ginza area. It is a beautiful four-story venue, complete with a theater (where one can sit and receive non-stop sessions on all of Apple’s products) and, of course